Schistosomiasis vaccine development--the current picture.
Development of a vaccine for schistosomiasis, a parasitic disease currently affecting over 200 million people worldwide, has been targeted as a priority by the World Health Organisation. Research demonstrating the ability of humans to acquire natural immunity to schistosome infection, together with the successful use of attenuated vaccines in animals both under laboratory and field conditions, suggest that development of a human vaccine is feasible. Attenuated vaccines for schistosomiasis are considered neither safe nor practicable for human use, however, and therefore other approaches must be considered. This review examines progress currently being undertaken in a number of different areas towards achieving the goal of a safe and effective human vaccine for schistosomiasis.
Waine
G J
GJ
Molecular Parasitology Unit, Queensland Institute of Medical Research, Australia. garyW@qimr.edu.au
McManus
D P
DP
D000818:Animals; D015801:Helminth Proteins / Q000276:immunology; D006801:Humans; D012547:Schistosoma / Q000254:growth & development / Q000276:immunology; D012552:Schistosomiasis / Q000276:immunology / Q000517:prevention & control*; D014612:Vaccines / Q000302:isolation & purification*; D014613:Vaccines, Attenuated / Q000302:isolation & purification; D014614:Vaccines, Synthetic / Q000302:isolation & purification
D015801:Helminth Proteins; D014612:Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic